{
    "clinical_study": {
        "@rank": "70573", 
        "acronym": "STARBEAM", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo adjunct to 10 mg Donepezil"
            }, 
            {
                "arm_group_label": "Lu AE58054 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "Lu AE58054 adjunct to 10 mg Donepezil"
            }, 
            {
                "arm_group_label": "Lu AE58054 30 mg", 
                "arm_group_type": "Experimental", 
                "description": "Lu AE58054 adjunct to 10 mg Donepezil"
            }
        ], 
        "brief_summary": {
            "textblock": "To establish efficacy of Lu AE58054 as adjunctive therapy to donepezil for symptomatic\n      treatment of patients with mild-to-moderate Alzheimer's disease (AD)."
        }, 
        "brief_title": "Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil", 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient has a knowledgeable and reliable caregiver.\n\n          -  The patient is an outpatient.\n\n          -  The patient has probable AD.\n\n          -  The patient has mild to moderate AD.\n\n          -  Stable treatment with donepezil.\n\n          -  The patient, if a woman, must have had her last natural menstruation \u226524 months prior\n             to baseline, OR be surgically sterile.\n\n          -  The patient, if a man, agrees to protocol-defined use of effective contraception if\n             his female partner is of childbearing potential, OR must have been surgically\n             sterilised prior to the screening visit.\n\n        Exclusion Criteria:\n\n          -  The patient has evidence of any clinically significant neurodegenerative disease, or\n             other serious neurological disorders other than AD.\n\n          -  The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition,\n             Text Revision (DSM-IV-TR) Axis I disorder other than AD.\n\n          -  The patient has evidence of clinically significant disease.\n\n          -  The patient's donepezil therapy is likely to be interrupted or discontinued during\n             the study.\n\n          -  The patient is currently receiving memantine or has taken memantine within 2 months\n             prior to screening.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "840", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006641", 
            "org_study_id": "14862A", 
            "secondary_id": "2012-004764-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Once daily, matching placebo capsules, orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Lu AE58054 10 mg", 
                    "Lu AE58054 30 mg"
                ], 
                "description": "Once daily, encapsulated tablets, orally", 
                "intervention_name": "Lu AE58054", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Donepezil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33186"
                }, 
                "name": "US303"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) total score", 
            "measure": "Change in cognition", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006641"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score", 
                "measure": "Change in global impression", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score", 
                "measure": "Change in functioning", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Change in Neuropsychiatric Inventory (NPI) total score", 
                "measure": "Change in behavioural disturbance", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Change in single NPI item scores", 
                "measure": "Change in individual behavioural disturbance items", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Change in NPI Anxiety item score based on a pre-specified NPI Anxiety score at Baseline", 
                "measure": "Change in anxiety", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Based on pre-specified ADAS-Cog, ADCS-ADL23, and ADCS-CGIC changes", 
                "measure": "Clinical response", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Based on pre-specified ADAS-Cog, ADCS-ADL23, and ADCS-CGIC changes", 
                "measure": "Clinical worsening", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "description": "Change in Mini Mental State Examination (MMSE)", 
                "measure": "Change in cognitive aspects of mental function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Change in EuroQol 5-dimensional 3-layer (EQ-5D-3L), a measure of health-related quality of life", 
                "measure": "Change in health-related quality of life (EQ-5D-3L)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Change in EQ-5D-3L Visual Analogue Scale (EQ-5D-3L VAS)", 
                "measure": "Change in health-related quality of  (EQ-5D-3L VAS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Overview of AEs", 
                "measure": "Number of patients with adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks and a 4-week safety follow up"
            }, 
            {
                "measure": "Proportion of patients who withdrew due to intolerance to treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "description": "Columbia Suicide Severity Rating Scale (C-SSRS)", 
                "measure": "Risk of suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}